Source: Annual Congress 2010 - Combination therapy in asthma and COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
K. Perrin, M. Wijesinghe, M. Williams, M. Weatherall, R. Beasley (Wellington, New Zealand). Does combination therapy lead to better adherence in asthma?. Eur Respir J 2010; 36: Suppl. 54, 1206

Member's Comments

No comment yet.

Related content which might interest you: Does adherence to ICS/LABA therapy affect response to mepolizumab in the treatment of severe asthma? Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Does azithromycin-prednisolone combination therapy have additive effects than single therapy in patients with persistent asthma? Source: Annual Congress 2009 - Aspects of uncontrolled asthma Year: 2009 Are a degree of asthma therapy related to asthma control impairment? Source: Eur Respir J 2003; 22: Suppl. 45, 370s Year: 2003 Looking back to go forward: adherence to inhaled therapy before biologic therapy in severe asthma Source: Eur Respir J, 55 (5) 2000954; 10.1183/13993003.00954-2020 Year: 2020 Adherence to asthma treatment: Can it be improved in general practice? Source: Annual Congress 2012 - Inflammation in airway diseases: diagnosis and management Year: 2012 Does the choice of ICS/LABA regimen influence exacerbation rates in asthma patients with high as-needed use? Source: Annual Congress 2007 - Recent advances in our understanding of the treatment of asthma Year: 2007 Does a formal prednisolone absorption test lead to improved control in difficult-to-treat asthma? Source: Annual Congress 2012 - Asthma treatment: efficacy and safety Year: 2012 Early treatment response may predict long-term mepolizumab benefit in severe asthma Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies Year: 2019 An intervention to modify patients‘ beliefs about maintenance therapy and improve adherence to medication Source: Eur Respir J 2005; 26: Suppl. 49, 46s Year: 2005 COPD exacerbations and adherence to treatment improvement:what goal can be achieved? Source: Virtual Congress 2020 – Inhaler devices in COPD: technical advances, adherence studies and more Year: 2020 Less is more: the impact of maintenance treatment adherence in severe asthma clinical trials Source: Eur Respir J, 53 (5) 1900599; 10.1183/13993003.00599-2019 Year: 2019 How often do asthma patients claim prescribed therapy? Source: International Congress 2017 – Asthma from childhood to adulthood and ACOS Year: 2017 Budesonide/formoterol maintenance and reliever therapy compared to conventional best practice in the treatment of persistent asthma Source: Eur Respir J 2007; 30: Suppl. 51, 616s Year: 2007 Who should receive which biologic and why? Current and future approaches in severe asthma patients Source: Virtual Congress 2021 – Linking scientific mechanisms to recent clinical therapeutic advances in airway disease: why, who, when and what? Year: 2021 Omalizumab improves asthma control in patients receiving high-dose ICS and multiple other controller therapies and who have continuing impairment of lung function and asthma symptoms Source: Annual Congress 2007 - Improving asthma therapy - new findings in established and experimental treatment modalities Year: 2007 Is antibiotic treatment during asthma exacerbation necessary ? Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies Year: 2017 Suboptimal asthma control in patients receiving long-term maintenance therapy Source: Annual Congress 2006 - The challenges of managing asthma in primary care Year: 2006 The way to improve the steroid sensitivity of target cells of patients with severe therapy resistant asthma Source: Eur Respir J 2006; 28: Suppl. 50, 313s Year: 2006